{"id":"NCT00344318","sponsor":"GlaxoSmithKline","briefTitle":"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine","officialTitle":"To Assess the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Pneumococcal Conjugate Vaccine Compared to Prevenar™, Co-administered With DTPw-HBV/Hib & OPV or IPV Vaccines as a 3-dose Primary Immunization Course During the First 6 Months of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-08-07","primaryCompletion":"2007-04-27","completion":"2007-10-17","firstPosted":"2006-06-26","resultsPosted":"2018-12-07","lastUpdate":"2018-12-07"},"enrollment":806,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Streptococcal"],"interventions":[{"type":"BIOLOGICAL","name":"Pneumococcal conjugate vaccine GSK1024850A","otherNames":[]},{"type":"BIOLOGICAL","name":"Prevenar","otherNames":[]},{"type":"BIOLOGICAL","name":"Tritanrix-HepB","otherNames":["DTPw-HBV"]},{"type":"BIOLOGICAL","name":"Hiberix","otherNames":["Hib"]},{"type":"BIOLOGICAL","name":"Polio Sabin.","otherNames":["OPV"]},{"type":"BIOLOGICAL","name":"Poliorix.","otherNames":["IPV"]}],"arms":[{"label":"Synflorix 1 Group","type":"EXPERIMENTAL"},{"label":"Synflorix 2 Group","type":"EXPERIMENTAL"},{"label":"Prevenar 1 Group","type":"ACTIVE_COMPARATOR"},{"label":"Prevenar 2 Group","type":"ACTIVE_COMPARATOR"}],"summary":"This study will evaluate safety, reactogenicity and immunogenicity of GSK Biologicals' pneumococcal conjugate vaccine compared to Prevenar™ when co-administered with DTPw-HBV/Hib and OPV or IPV vaccines, according to 2 different schedules: 6-10-14 weeks or 2-4-6 months of age.\n\nThe study has 2 groups.\n\n* One group of subjects will receive a 3-dose primary vaccination with the GSK Biologicals' pneumococcal conjugate vaccine (three different lots will be used and randomly allocated).\n* The 2nd group of subjects will receive a 3-dose primary vaccination with Prevenar™.\n\nAll children will receive concomitantly DTPw-HBV/Hib and OPV or IPV vaccines. This protocol posting deals with objectives \\& outcome measures of the primary study. The objectives \\& outcome measures of the Booster study are presented in a separate protocol posting (NCT number =00547248).","primaryOutcome":{"measure":"Number of Subjects Reporting Rectal Temperature Above (>) 39.0 Degrees Celsius (°C)","timeFrame":"Within 4 day (Days 0-3) after each dose and across doses","effectByArm":[{"arm":"Synflorix Pooled Group","deltaMin":31,"sd":null},{"arm":"Prevenar Pooled Group","deltaMin":6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"6 Weeks","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":12},"locations":{"siteCount":7,"countries":["Philippines","Poland"]},"refs":{"pmids":["19325452","19325451","19325447"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":300},"commonTop":["Irritability","Pyrexia","Erythema","Somnolence","Swelling"]}}